ERIC DOBMEIER - 24 Apr 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Role
President, CEO, Director
Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
24 Apr 2023
Net transactions value
-$476,317
Form type
4
Filing time
26 Apr 2023, 17:19:14 UTC
Previous filing
15 Feb 2023
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KDNY Common Stock Options Exercise $10,500 +25,000 +8.3% $0.4200* 326,138 24 Apr 2023 Direct
transaction KDNY Common Stock Sale $513,528 -23,800 -7.3% $21.58 302,338 24 Apr 2023 Direct F1, F2
transaction KDNY Common Stock Sale $26,711 +1,200 +0.4% $22.26 301,138 24 Apr 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Stock Option (Right to Buy) Options Exercise $0 -25,000 -7.4% $0.000000 313,555 24 Apr 2023 Common Stock 25,000 $0.4200 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated December 22, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.22 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.22 to $22.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 The stock option vested as to 25% of the total shares monthly on March 6, 2021, and thereafter vests as to 1/48 of the total shares until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.